West Pharma (WST) Reports In-Line Q4 EPS, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
West Announces Fourth Quarter and Full-Year 2015 Results
February 18, 2016 7:00 AM ESTEXTON, PA -- (Marketwired) -- 02/18/16 -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth quarter and full-year 2015 and provided detailed financial guidance for the year 2016.
Executive Summary
Fourth-quarter 2015 reported sales of $359.7 million grew 2.8% over the prior-year quarter. Net sales at constant currency grew by 9.7% for the quarter. Full-year 2015 sales of $1.4 billion declined by 1.5% due to currency, with net sales at constant currency growing 7.2%. Fourth-quarter 2015 reported diluted EPS was $0.45. On an adjusted basis, diluted EPS was $0.47 and grew 4% from the same period last... More